Viewing Study NCT04079166


Ignite Creation Date: 2025-12-24 @ 4:09 PM
Ignite Modification Date: 2026-01-22 @ 6:20 PM
Study NCT ID: NCT04079166
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-19
First Post: 2019-08-16
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
Sponsor: Scancell Ltd
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module